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Abstract: Gastric cancer is one of the most common malignancies worldwide. However, 
genetic alterations leading to this disease are largely unknown. Gene amplification is one 
of the  most frequent genetic  alterations, which  is  believed to  play  a major role in  the 
development and progression of gastric cancer. In the present study, we identified three 
frequently  amplified  genes  from  30  candidate  genes  using  real-time  quantitative  PCR 
method, including ERBB4, C-MET and CD44, and further explored their association with 
clinicopathological characteristics and poor survival in a cohort of gastric cancers. Our  
data  showed  amplification  of  these  genes  was  significantly  associated  with  certain 
clinicopathological  characteristics,  particularly  tumor  differentiation  and  cancer-related 
death. More importantly, amplification of these genes was significantly related to worse 
survival,  suggesting  that  these  amplified  genes  may  be  significant  predictors  of  poor 
prognosis and potential therapeutic targets in gastric cancer. Targeting these genes may 
thus provide new possibilities in the treatment of gastric cancer. 
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1. Introduction 
Gastric cancer is one of the most common malignancies and remains the second leading cause of 
cancer-related death worldwide [1]. Over 70% of new cases and deaths occur in developing countries. 
The highest incidence rates are in Eastern Asia, Eastern Europe and South America, particularly China [2]. 
Although recent diagnostic and therapeutic advances have gradually improved clinical outcome of the 
patients with early gastric cancer, unfortunately, gastric cancer is usually diagnosed at an advanced 
stage  and  the  prognosis  is  still  poor  [3],
 reflecting  limited  advances  in  our  understanding  of  the 
pathogenesis of this disease. Thus, a better understanding of the molecular mechanisms and genetic 
alterations of gastric cancer may lead to new diagnostic and therapeutic strategies to this disease. 
Gene  amplification  is  one  of  the  most  frequent  genomic  alterations  found  in  human  cancers, 
including gastric cancer [4–6]. Increased gene dosage by this genetic event is a common mechanism 
for oncogene overexpression during tumorigenesis [7]. Generally, the amplified genes do not undergo 
additional damage by mutations, indicating that it is the enhanced levels of a wide-type protein that 
contributes  to  tumorigenesis  [7].  Like  other  types  of  genetic  alterations,  gene  amplification  also 
reflects the genetic instability of the tumor cells, and may confer diagnostic, prognostic, or therapeutic 
information for patient management [8]. 
Using  real-time  quantitative  PCR  method,  we  identified  three  frequently  amplified  genes  from  
30 candidate genes, including ERBB4, C-MET and CD44 genes, in 30 pairs of gastric cancer and 
normal gastric tissues, and further demonstrated that aberrant amplification of these genes significantly 
affected the clinical outcome in a cohort of clinically well-characterized gastric cancers. 
2. Results 
2.1. Highly Frequent Amplification of ERBB4, C-MET and CD44 in Gastric Cancer 
Real-time quantitative PCR assay was performed to analyze the copy number of thirty candidate 
genes in 30 pairs of gastric cancer and normal gastric tissues. With a gene copy number of 4 or more 
defined  as  gene  amplification,  we  found  that  ERBB4,  C-MET  and  CD44  genes  were  frequently 
amplified in gastric cancers, however, other genes were not or infrequently amplified in gastric cancers, 
ranging from 0 to 8% (data not shown). Subsequently, we used the same method to analyze the copy 
number of ERBB4, C-MET and CD44 genes in the 128 gastric cancers and 37 normal controls. The 
data showed that the prevalence of amplification of ERBB4, C-MET and CD44 was 67% (86/128), 
30% (39/128) and 66% (84/128), respectively, but not in the normal gastric tissues. Copy number of 
each gene corresponding to each individual case of gastric cancers and normal gastric tissues was 
showed in Figure 1. Statistical analysis showed that the copy number of each gene in gastric cancers 
was significantly higher than normal gastric tissues (Figure 1). Int. J. Mol. Sci. 2012, 13  4716 
 
 
Figure 1. The copy number of ERBB4, C-MET and CD44 genes corresponding to each 
individual case of gastric cancers and normal gastric tissues (circle). Real-time quantitative 
PCR was performed to evaluate their copy numbers in a cohort of gastric cancers and 
normal gastric tissues. Details are as described in Methods. Horizontal lines indicate a 95% 
confidence interval for the sample mean. T: tumor tissues; N: normal gastric tissues. 
 
2.2. Association of Amplification of ERBB4, C-MET and CD44 with Clinicopathological 
Characteristics in Gastric Cancer 
Because highly frequent amplification of ERBB4, C-MET and CD44 was demonstrated in gastric 
cancer, their association with clinicopathological characteristics was analyzed in a cohort of clinically 
well-characterized  gastric  cancers.  As  shown  in  Table  1,  there  was  a  positive  association  of 
amplification  of  ERBB4  (OR  =  2.62,  95%  CI  =  1.23–5.59,  P  <  0.05)  and  CD44  (OR  =  2.28,  
95% CI = 1.08–4.79, P < 0.05) with tumor differentiation. C-MET amplification was found to be 
significantly positively associated with tumor invasion (OR = 2.00, 95% CI = 1.03–3.89, P < 0.05). 
CD44 amplification was significantly positively associated with lymph node metastasis (OR = 2.23, 
95%  CI  =  1.05–4.73,  P  <  0.05).  Moreover,  our  data  also  showed  that  CD44  amplification  was 
significantly  positively  associated  with  the  number  of  lymph  node  metastasis  (OR  =  1.70,  
95% CI = 1.08–2.69, P < 0.05). Notably, there was a significantly positive association of amplification 
of these genes with cancer-related death (Table 1). In order to assess the independent association of 
gene amplification with age, tumor differentiation, tumor stage, lymph node metastasis and survival 
status,  we  conducted  multiple  multivariable  logistic  regressions  (Table  2).  Similar  to  univariate 
analysis, after adjustment, amplification of ERBB4 (OR = 2.95, 95% CI = 1.27–6.86, P < 0.05) and 
CD44 (OR = 2.49, 95% CI = 1.08–5.79, P < 0.05) remained significantly associated with poor tumor 
differentiation  (Table  2).  Similarly,  amplification  of  these  genes  remained  significantly  positively 
associated with cancer-related death (Table 2). 
Table 1. Amplification of individual genes in gastric cancer―univariate associations with 
clinicopathological characteristics (OR 
† and 95% CI). 
Genes  Male vs. Female  Age 
1  Tumor Localization 
2  Tumor Size 
3  Differentiation 
4 
ERBB4  0.97 (0.39–2.39)  1.12 (0.79–1.54)  0.82 (0.53–1.29)  0.88 (0.55–1.40)  2.62 (1.23–5.59) * 
C-MET  0.95 (0.38–2.41)  1.29 (0.90–1.85)  0.92 (0.59–1.44)  1.28 (0.80–2.05)  1.92 (0.87–4.27) 
CD44  1.06 (0.43–2.61)  1.15 (0.82–1.63)  0.80 (0.52–1.25)  0.88 (0.56–1.39)  2.28 (1.08–4.79) * Int. J. Mol. Sci. 2012, 13  4717 
 
 
Table 1. Cont. 
Genes  Tumor Invasion 
5  Tumor Stage 
6  Lymph Node Metastasis  No. of LNM 
7  Survival Status 
8 
ERBB4  1.09 (0.65–1.85)  1.21 (0.81–1.83)  1.88 (0.89–4.01)  1.56 (0.99–2.46)  3.06 (1.41–6.63) ** 
C-MET  2.00 (1.03–3.89) *  1.33 (0.86–2.08)  1.81 (0.80–4.09)  1.25 (0.82–1.92)  3.42 (1.51–7.71) ** 
CD44  1.28 (0.76–2.13)  1.37 (0.91–2.06)  2.23 (1.05–4.73) *  1.70 (1.08–2.69) *  4.08 (1.86–8.94) ** 
† OR: odds ratio with 95% confidence interval; 
1 Age (per 10 years); 
2 Tumor localization (gastric cardia; gastric body; 
gastric antrum); 
3 Tumor size (≤3 cm; >3 cm and ≤5 cm; >5 cm); 
4 Differentiation (well or moderate; poor or no differentiation); 
5 Tumor invasion (T1; T2; T3; T4); 
6 Tumor stage (I; II; III; IV); 
7 No. of LNM (lymph node metastasis) (0; 1–6; 7–
15; >16); 
8 Survival status (Alive vs. Dead); * P < 0.05; ** P < 0.01. 
Table  2.  Amplification  of  individual  genes  in  gastric  cancer―multivariable  models 
assessing  age,  differentiation,  tumor  stage,  lymph  node  metastasis  and  survival  status  
(OR 
† and 95% CI). 
Genes  Age 
1  Differentiation 
2  Tumor Stage 
3  Lymph Node 
Metastasis  Survival Status 
4 
ERBB4  1.22 (0.81–1.83)  2.95 (1.27–6.86) *  0.73 (0.39–1.39)  1.24 (0.38–3.98)  3.33 (1.28–8.67) * 
C-MET  1.32 (0.88–1.97)  2.17 (0.92–5.14)  0.88 (0.45–1.70)  0.80 (0.23–2.84)  3.81 (1.35–10.8) * 
CD44  1.19 (0.79–1.78)  2.49 (1.08–5.79) *  0.80 (0.43–1.51)  1.20 (0.38–3.84)  4.23 (1.62–11.0) ** 
† OR: odds ratio with 95% confidence interval; 
1 Age (per 10 years); 
2 Differentiation (well/moderate; poor/no 
differentiation); 
3 Tumor stage (I; II; III; IV); 
4 Survival status (Alive vs. Dead); * P < 0.05; ** P < 0.01. 
2.3. The Effect of Amplification of ERBB4, C-MET and CD44 on Poor Survival in Gastric Cancer 
The  Kaplan-Meier  estimator  of  the  survivorship  function  was  used  to  evaluate  the  impact  of 
amplification of these three genes on the survival of gastric cancer patients. The survival of gastric 
cancer patients with and without gene amplification was compared using the log-rank test. As shown 
in Figure 2, amplification of ERBB4, C-MET and CD44 significantly affected the poor survival of 
gastric cancer patients. 
Figure 2. The effect of amplification of ERBB4, C-MET and CD44 on poor survival in 
gastric cancer. Kaplan-Meier survival curves were made according to the presence of gene 
amplification  in  a  cohort  of  gastric  cancers.  The  patients  with  gene  amplification  had 
significantly  shorter  survival  times  than  the  patients  without  gene  amplification.  
Am, amplification; +, harboring gene amplification; −, the lack of gene amplification. 
 
Numerous evidences showed that residual tumor after surgery is an independent risk factor for 
gastric cancer patients. We thus attempted to evaluate the effect of residual tumor after surgery on the Int. J. Mol. Sci. 2012, 13  4718 
 
 
survival of gastric cancer patients. As shown in Figure 3, the patients with residual tumor after surgery 
had significantly shorter survival times than the patients without residual tumor (343.2 months vs. 
601.2 months on average, P = 0.03). Given the impact of residual tumor after surgery on poor survival 
in  gastric  cancer,  we  excluded  the  patients  with  residual  tumor  to  explore  the  effect  of  gene 
amplification on poor prognosis of gastric cancer patients. Similar to the findings in Figure 2, the 
patients with gene amplification had shorter survival times than the patients without gene amplification 
(ERBB4: 508.8 months vs. 777.6 on average, P = 0.002; C-MET: 382.8 months vs. 690.0 months on 
average, P = 0.0005; CD44: 490.8 months vs. 798.0 months on average, P = 0.0002) (Figure 4). 
Multivariate Cox regression analysis indicated that gene amplification may be served as a predictor of 
poor  prognosis  for  gastric  cancer  patients  (ERBB4:  HR  =  2.00,  95%  CI  =  1.02–3.86,  P  =  0.04;  
C-MET: HR = 2.10, 95% CI = 1.20–3.69, P = 0.01; CD44: HR = 2.59, 95% CI = 1.34–5.01, P = 0.005) 
as an independently variable with respect to gender, age, differentiation, lymph node metastasis, and 
tumor stage (Table 3).  
Figure 3. The effect of residual tumor after surgery on poor survival in gastric cancer. 
Survival was evaluated according to the presence of residual tumor after surgery in gastric 
cancers. Kaplan–Meier survival curves show that the patients with residual tumor had a 
significantly shorter survival time than the patients without residual tumor (P = 0.002).  
+, the patients with residual tumor; −, the patients without residual tumor. 
   
Figure 4. The effect of amplification of ERBB4, C-MET and CD44 on poor survival of 
gastric  cancer  patients  without  residual  tumor  after  surgery.  Kaplan–Meier  analysis  of 
survival was performed according to the status of gene amplification in a cohort of gastric 
cancers. The patients with gene amplification had poorer survival than the patients without 
gene  amplification.  Am,  amplification;  +,  harboring  gene  amplification;  −,  the  lack  of  
gene amplification. 
 
P =0.002 
P = 0.002 Int. J. Mol. Sci. 2012, 13  4719 
 
 
Table 3. The effect of amplification of ERBB4, C-MET and CD44 on overall survival in 
gastric cancer using multivariate Cox regression analysis. 
Covariate  Gene Amplification  P Value  HR *  95% CI 
Gender 
Age 
Differentiation 
Lymph node metastasis 
Tumor stage 
ERBB4  0.04  2.00  1.02–3.86 
C-MET  0.01  2.10  1.20–3.69 
CD44  0.005  2.59  1.34–5.01 
* HR: Hazard ratio; CI: confidence interval; Significant at P < 0.05. 
Gastric cancer is chronic proliferative disease characterized by genetic alterations of multiple genes, 
including gene amplification. In the present study, a high prevalence of concomitant amplification of  
2 of 3 genes was found in gastric cancer, ranging from 28% (36/128) to 60% (77/128). As shown in 
Figure 5, concomitant amplification of 2 of 3 genes significantly shortened survival times (ERBB4/C-MET: 
378.0 months vs. 795.6 on average, P = 0.001; ERBB4/CD44: 483.6 months vs. 817.2 months on average,  
P = 0.0004; C-MET/CD44: 372.0 months vs. 822.0 months on average, P < 0.0001), and might be 
more prognostic of poor survival than amplification of individual gene in gastric cancer. 
Figure 5. The effect of concomitant amplification of two of three genes on poor survival in 
gastric  cancer.  Survival  was  evaluated  according  to  the  presence  of  concomitant 
amplification of two of three genes in a number of gastric cancer patients without residual 
tumor after surgery. The patients with gene amplification had significantly shorter survival 
times  than  the  patients  without  gene  amplification.  +/+,  harboring  concomitant 
amplification of two genes; −/−, the lack of gene amplification. 
 
3. Discussion  
Although gastric cancer is a lethal disease around the world, the causes of gastric cancer are not 
completely understood. What is clear is that gastric cancer is a multistep process involving multiple 
genetic  and epigenetic events,  such  as gene  amplification.  Gene amplification is frequent in  solid 
tumors and represents one of the major molecular pathways through which the oncogenic potential of 
proto-oncogenes is overactivated during tumorigenesis [7,8]. Thus, gene amplification in general and 
specifically amplicons, have importance for both prognosis and targeted therapies in human cancers, 
including gastric cancer [9–12]. Int. J. Mol. Sci. 2012, 13  4720 
 
 
In the present study, we identified three frequently amplified genes in a cohort of well-characterized 
gastric cancer using real-time quantitative PCR method, including ERBB4, C-MET and CD44. ERBB4 
(or HER4) is a member of the Tyr protein kinase family and the epidermal growth factor receptor 
subfamily, and plays an important role in normal cell growth and in neoplastic transformation [13]. 
ERBB4 amplification, resulting in its overexpression and ligand-independent activation has been found 
in a variety of human malignancies [6,14]. C-MET oncogene encodes the receptor tyrosine kinase 
(RTK) for hepatocyte growth factor (HGF) and regulates genetic programs leading to cell growth, 
invasion and protection from apoptosis during tumorigenesis [15]. C-MET is frequently amplified in 
human  cancers,  including  gastric  cancer  [16,17].  Its  amplification  is  closely  associated  with  poor 
prognosis of cancer patients and resistance to tyrosine kinase inhibitors [16–20].
 CD44 is a receptor for 
hyaluronic acid (HA), which plays an important role in cell migration, tumor growth and progression 
through its affinity for HA, possibly also through its affinity for other ligands such as osteopontin, 
collagens,  and  matrix  metalloproteinases  (MMPs)  [21].
  Accumulating  evidences  have  shown  that 
CD44 is abundantly expressed in cancer-initiating cells (CICs), and has thus been implicated as a CIC 
marker in several malignancies of haematopoietic and epithelial origin, including gastric cancer [21,22].
 
Moreover,  CD44  amplification  is  also  found  in  gastric  cancer  [6].  Notable,  there  was  a  higher 
amplification frequency of these genes in the present study than that of studies carried out in Europe 
and the US [23]. One possibility is that the different dietary and environmental factors, such as nitrates, 
carbohydrates and salt, may potentially cause these distinct genetic alterations in gastric carcinogenesis [24]. 
Given gene amplification plays a critical role in gastric tumorigenesis, we investigated their clinical 
significances and prognostic values in a cohort of gastric cancer patients who had known survival data. 
Our  data  showed  that  amplification  of  these  genes  was  closely  associated  with  poor  tumor 
differentiation  and  cancer-related  death,  suggesting  that  these  genes  may  contribute  to  oncologic 
outcomes  of  gastric  cancer  patients.  More  importantly,  similar  to  observations  in  the  previous  
studies [17], C-MET amplification was correlated with poor survival of gastric cancer patients in the 
present study. Notably, our data showed that amplification of ERBB4 and CD44 was significantly 
associated with poor prognosis in gastric cancer, is new to the literature. 
To date, inhibitors and antibodies targeting specific molecules are vigorously being developed, and 
some have been demonstrated to be effective in clinical settings, including gastric cancer [25,26].  
In the present study, we identified three frequently amplified genes and demonstrated that they were 
significantly associated with clinical outcome in gastric cancer, suggesting that they may be served as 
potential therapeutic targets for gastric cancer. Moreover, the prognostic markers may have another 
role in predicting and guiding the clinical treatment of cancer patients by allowing the identification of 
patients  suited  to  current  therapies.  For  example,  C-MET  amplification  may  identify  a  subset  of 
epithelial cancers with extreme sensitivity to the selective tyrosine kinase inhibitor and define a patient 
group that is appropriate for clinical trials of targeted therapy using MET inhibitors [27]. Int. J. Mol. Sci. 2012, 13  4721 
 
 
4. Experimental Section 
4.1. Patients  
With the approval of our institutional review board and human ethics committee, where required, 
we studied 128 patients with gastric cancer who underwent surgery at the First Affiliated Hospital of 
Xi’an Jiaotong University School of Medicine from 1999 to 2006. A total of 37 tissues from the 
patients  with  chronic  gastritis  were  obtained  from  the  First  Affiliated  Hospital  of  Xi’an  Jiaotong 
University School of Medicine as normal controls. None of these patients received chemotherapy and 
radiotherapy before the surgery. Informed consent was obtained from each patient before the surgery. 
The histologic diagnosis of tumors was made and agreed upon by at least two senior pathologists at 
Department  of  Pathology  of  the  Hospital  based  on  World  Health  Organization  (WHO)  criteria. 
Relevant clinicopathologic characteristics were obtained from the patients’ files or by interview with 
the patients or their relatives, and the details were summarized in Table 4. 
Table 4. Characteristics of patients with gastric cancer. 
Characteristics  No. of Patients (%) 
Gender   
Male  101 (78.9) 
Female  27 (21.1) 
Age, years   
Mean  59.42 
SD  13.062 
Tumor localization   
gastric cardia  35 (27.3) 
gastric body  33 (25.8) 
gastric antrum  60 (46.9) 
Tumor size (cm
3)   
≤3  43 (33.6) 
3-5  46 (35.9) 
>5  39 (30.5) 
Differentiation   
well/moderate  53 (41.4) 
poor/undifferentiation  75 (58.6) 
Tumor invasion   
T1  14 (10.9) 
T2  22 (17.2) 
T3  90 (70.3) 
T4  2 (1.6) 
TNM stage   
I  29 (22.7) 
II  20 (15.6) 
III  73 (57.0) 
IV  6 (4.7) Int. J. Mol. Sci. 2012, 13  4722 
 
 
Table 4. Cont. 
Residual tumor   
Yes  14 (10.9) 
No  114 (89.1) 
Lymph node metastasis (LNM)    
Yes  80 (62.5) 
No  48 (37.5) 
No. of LNM   
N0  48(37.5) 
N1 (1-6)  47 (36.7) 
N2 (7-15)  27 (21.1) 
N3 (≥16)  6 (4.7) 
Survival status   
Dead  66 (51.6) 
Alive  62 (48.4) 
4.2. Tissues and DNA Preparation 
Serial sections from each tumor sample were cut. One section (5 µm) was stained by hematoxylin 
and eosin (H & E), and was marked as a tumor representative tissue by an expert surgical pathologist 
for gastric cancer. The next section (8 μm) was deparaffinized and stained with hematoxylin. Tumor 
tissues were isolated by manual microdissection under an inverted microscope using the marked H & E 
section for target tissue identification. Genomic DNA was extracted from isolated tissues as previously 
described  [28].  Briefly,  the  tissues  dissected  were  first  treated  with  xylene  for  12  hours  at  room 
temperature to remove the paraffin. All tissues  were subsequently subjected to digestion with 1% 
sodium dodecyl sulfate (SDS) and proteinase K at 48 °C  for 48 to 72 hours with addition of several 
spiking aliquots of concentrated proteinase K to facilitate digestion. Genomic DNA was isolated from 
the  digested  tissues  followed  by  standard  phenol-chloroform  extraction  and  ethanol  precipitation 
protocol, and stored at −80 °C  until use. 
4.3. Copy Number Analysis 
We analyzed the copy number of candidate genes in gastric cancers and normal gastric tissues by 
real-time quantitative PCR technique on a CFX384 Thermal Cycler Dice
TM real-time PCR system 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA) as described previously [29]. This method was well 
established and validated by florescence in situ hybridization (FISH) [29,30], which has been widely 
used in the various human cancers [28–32]. Specific primers and TaqMan probes were designed using 
Primer Express 3.0 (Applied Biosystems: Foster City, CA, USA, 2004) to amplify these genes and the 
internal  reference  gene  β-actin.  The  primers  and  TaqMan  probes  for  ERBB4,  C-MET,  CD44  and  
β-actin genes in the present study were presented in Table 5. The primers and TaqMan probes for other 
27  genes  need  be  requested,  including  SHFM1,  CARD4,  ELN,  ARF5,  SLC25A40,  NRAS,  CDK5, 
CREM, LMO2, DNMT1, FMR2, PSPHL, KRAS, PEG10, CDC2L5, HRAS, MGAM, ZP3, EPO, GUSB, 
ZPBP, TMEM60, PEPIN1, BRAF, AHR, DNMT3B and EZH2. All TaqMan probes were labeled with 
5'-FAM (6-carboxyfluorescein, fluorescent reporter) and 3'-TAMRA (6-carboxy-tetramethylrhodamine, Int. J. Mol. Sci. 2012, 13  4723 
 
 
fluorescent  quencher).  Using  a  PCR  protocol  described  previously  [29],  PCR  amplification  were 
carried  out  in  buffer  containing  16.6  mM  ammonium  sulfate,  67  mM Tris  base,  2.5  mM  MgCl2,  
10 mM 2-mercaptoethanol, 0.1% DMSO, 0.2 mM each of dATP, dCTP, dGTP and dTTP, 600 nM 
each of forward and reverse primers, 200 nM TaqMan probe, 0.6 unit Platinum Taq polymerase and 
2% Rox reference dye. Each sample was run in triplicate, and β-actin was run in parallel to standardize 
the input DNA. Standard curves were established using serial dilutions of normal leukocyte DNA with 
a quantity range of 3.75 to 60 ng per 2 μL. The specificity of real-time quantitative PCR for these 
genes was confirmed by running thee PCR products on a 1.5% agarose gel to show single specific 
bands  of  the  PCR  products  at  the  expected  sizes  (data  not  shown).  The  efficiency  of  real-time 
quantitative PCR assays for each target was shown in Table 5. Gene amplification was defined by a 
copy number ≥4. 
Table 5. The primer and TaqMan probe sequences used in this study. 
Genes  Forward Primer Sequence 
(5'→3') 
Probe Sequence  
(5'→3') 
Reverse Primer Sequence 
(5'→3') 
Amplification 
Efficiency 
(%) 
ERBB4  CCCTGAAGCCAGGCACTGT   6FAM-CTGCCGCCTCCACCTTACAGACACC-
TAMRA  
CCTAAAAAACCACAAC
TGAGCTTACA  
84.2 
C-MET  ACCTGCCAGCGACATGTCTT   6FAM-CCACAATCATACTGCTGACA-TAMRA   GACACTGGCTGGGCTCT
TCTATC  
84.1 
CD44  GCTCTGAGCATCGGATTTGAG   6FAM-CCTGCAGGTAAGAGACCAGCACCCG-
TAMRA  
AGGCCGCCAGCTTTCC   85.0 
β-Actin  TCACCCACACTGTGCCCATCT
ACGA  
6FAM-ATGCCCTCCCCCATGCCATCC-TAMRA  TCGGTGAGGATCTTCAT
GAGGTA 
95.0 
4.4. Statistical Analysis 
The Mann–Whitney U test was used to compare copy number of these genes between gastric cancer 
and normal gastric tissues. Association of gene amplification with clinicopathological characteristics 
was assessed univariately using the SPSS statistical package (version 11.5; IBM Corporation: Chicago, 
IL,  USA,  2003).  Multivariate  models  were  then  developed  that  adjusted  for  the  most  important 
covariates,  including  age,  differentiation,  tumor  stage,  lymph  node  metastasis  and  survival  status. 
Survival length was determined from the day of primary tumor surgery to the day of death or last 
clinical  follow-up.  The  Kaplan–Meier  method  was  used  for  survival  analysis  grouping  with  gene 
amplification. Differences between curves were analyzed using the log-rank test. Multivariate Cox 
regression analysis was used to evaluate the effect of gene amplification on survival of independently 
of gender, age, differentiation, lymph node metastasis, and tumor stage. All statistical analyses were 
performed using the SPSS statistical package. P values < 0.05 were considered significant. 
5. Conclusions  
In summary, we identified three genes that were frequently amplified from thirty candidate genes in 
cancerous tissues, but not normal gastric tissues, and demonstrated that amplification of these genes 
was closely associated with clinicopathological characteristics, particularly tumor differentiation and Int. J. Mol. Sci. 2012, 13  4724 
 
 
cancer-related death. Importantly, amplification of these genes was significantly associated with poor 
survival in gastric cancer. Thus, these aberrantly amplified genes may be used as useful markers in 
evaluating poor prognosis and potential therapeutic targets for gastric cancer. 
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